Almirall SA
MAD:ALM

Watchlist Manager
Almirall SA Logo
Almirall SA
MAD:ALM
Watchlist
Price: 10.66 EUR 0.76% Market Closed
Market Cap: 2.3B EUR

EV/EBITDA
Enterprise Value to EBITDA

12.1
Current
10.1
Median
12.6
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
12.1
=
Enterprise Value
2.3B EUR
/
EBITDA
188.7m EUR
Market Cap EV/EBITDA
ES
Almirall SA
MAD:ALM
2.3B EUR 12.1
US
Eli Lilly and Co
NYSE:LLY
676.4B USD 32.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
367.9B USD 12.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 12.9
CH
Roche Holding AG
SIX:ROG
206.7B CHF 9.4
CH
Novartis AG
SIX:NOVN
181.7B CHF 10.2
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 130.8
US
Merck & Co Inc
NYSE:MRK
195.2B USD 8.4
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
132.6B USD 7.3
EBITDA Growth EV/EBITDA to Growth
ES
Almirall SA
MAD:ALM
Average EV/EBITDA: 394.9
12.1
19%
0.6
US
Eli Lilly and Co
NYSE:LLY
32.8
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.4
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.6

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
10.1
2-Years Forward
EV/EBITDA
8.3
3-Years Forward
EV/EBITDA
7.2